6 Red Days In A Row: CRISPR Therapeutics Stock Is Down 18%

6 Red Days In A Row: CRISPR Therapeutics Stock Is Down 18%

A multi-day slide in this gene editing stock is drawing attention to its underlying financial metrics.

CRISPR Therapeutics (CRSP), a gene editing company, focuses on developing gene-based medicines for serious diseases. The market has now pushed its stock lower for 6 consecutive trading days, a slide that has erased about $1.1 billion from the company's market value. The cumulative loss over this period is 18.5%.

The company's lead product candidate is CTX001, an ex-vivo therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease.

CRSP Versus The S&P 500, Streak And Beyond

Here is how CRSP stock stacks up against the S&P 500 over the streak and the periods around it:

The stock's decline is happening alongside strained fundamentals.

This six-day move is specific to the company, not the broader market. Over the same 6 trading days the S&P 500 returned +0.1%. The selling pressure coincides with financial metrics that stand in sharp contrast to market medians. Revenue over the last twelve months declined 97.1%, while the S&P 500 median saw revenue growth of 7.5%.

CRISPR Therapeutics' operating margin is -64639.5%, against a median of 18.4% for the index. This kind of losing streak is not entirely isolated; 33 S&P 500 stocks are currently on losing streaks of 3 days or more.

A streak is a signal to re-evaluate, not a command to act.

A persistent move in one direction is information. It tells you where market momentum and attention are currently focused. It is not, however, an instruction to buy or sell. The disciplined response is to use the new attention on the stock as a reason to check the business fundamentals against the price. The numbers here provide a starting point for that work.

If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.

And for anyone who would rather own the whole group than one company's story, a biotech ETF like XBI covers the whole group. That way, no single company's next surprise decides the outcome.

CRSP Has Fallen 77% From A Peak Before

A stock that falls day after day is a live lesson in what single-name exposure feels like. CRSP itself has fallen 77% from a peak within the past five years, and a fall like that lands very differently when one position carries too much of your wealth. Knowing what a repeat would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.